A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis - NCT05155085

The proportion of subjects who achieve an IGA score of 0 or 1 and a reduction of ≥2 points on a 0-4 IGA scale, Compare efficacy of lirentelimab with placebo in subjects with moderate-to-severe AD as estimated by the proportion of subjects who achieve EASI-75, Proportion of subjects with improvement of pruritus numeric rating scale (NRS) ≥4